Findoc-cll.in/4th_qtr_result

COLINZ LABORATORIES LIMITED
A-101, Pratik Ind. Estate, Next to Fortis Hospital, Mulund-Goregaon Link Road, Mumbai - 400 078.

AUDITED FINANCIAL RESULTS FOR THE YEAR ENDED : 31ST MARCH 2014.

						(Rupees in '000')
			Un -audited			Audited
S. No.	Particulars		Quarter ended			Year Ended	Year Ended
			31.03.2014	31.12.2013	31.03.2013	31.03.2014	31.03.2013
PART-I
1	(a) Income from Operation
		Gross Sales	18,213	19,323	17,481	77,960	76,818
		Less: Excise Duty	237	1,036	1,280	3,932	5,282
	Net Sales		17,976	18,287	16,201	74,028	71,536
	(b) Other Operating Income		-	-	-	-	323
	Total Income from Operation		17,976	18,287	16,201	74,028	71,859
2	Expenditure		-	-	-	-	-
	(a)	Consumption of Materials	409	5,884	3,152	18,048	21,402
	(b)	Purchase of Goods Traded	6,651	3,503	1,144	13,275	5,460
	(c)	(Increase)/Decrease in stock in trade	1,785	(1,467)	2,434	2,012	1,702
	(d)	Staff Cost	5,758	6,730	5,566	25,313	25,748
	(e)	Depreciation	656	656	659	2,624	2,619
	(f)	Other Expenditure	2,587	3,047	2,556	11,923	12,083
	Total Expenditure		17,846	18,353	15,511	73,195	69,014
3	Profit/Loss from Operation Before Other Income (1-2)		130	-66	690	833	2,845
4	Other Income/(Loss)		287	636	266	1,273	775
5	Profit/Loss before Interest & Exceptional items (3+4)		417	570	956	2,106	3,620
6	Interest		(125)	270	467	841	2,021
7	Profit/Loss after Interest but before exceptional items (5-6)		542	300	489	1,265	1,599
8	Exceptional items		-	-	-	-	-
9	Profit/Loss before Tax (7-8)		542	300	489	1,265	1599
10	Tax Expenses (Provision for Taxation): Current tax		-	-	-	229	297
		Deffered tax	-	-	-	371	504

11	Net Profit/Loss after Tax (9-10)		542	300	489	665	798
12	Paid up Equity Share Capital (Face Value 10/- Per Share)		354,35	354,35	354,35	354,35	354,35
12	[Net of allotment money in arrears]		354,35	354,35	354,35	354,35	354,35
13	Reserves Excluding Revaluation Reserves		-	-	-	9,093	8,428
14	Earning per share (EPS) before extraordinary item (not Annualised)		-	-	-	-	-
	Basic & Diluted		-	-	-	0.15	0.17
PART-II	A. PARTICULARS OF SHAREHOLDING
1	Public Shareholding
	i)	Number of Shares	28,94,901	28,94,901	29,04,901	28,94,901	29,04,901
	ii)	Percentage of shareholding	63.33%	63.33%	63.55%	63.33%	63.55%
2	Promoters and promoter group Shareholding
	a)	Pledged/Encumbered
	i)	Number of shares	-	-	-	-	-
	ii)	Percentage of shares (as a % of the total shareholding of	-	-	-	-	-
		promoter and promoter group)
	iii)	Percentage of shares (as a% of the total share capital of the company)	-	-	-	-	-
	b)	Non-encumbered
	i)	Number of Shares	1,676,099	1,676,099	1,666,099	1,676,099	1,666,099
	ii)	Percentage of shares (as a% of the total shareholding	36.67%	36.67%	36.45%	36.67%	36.45%
		of promoter and promoter group)
	iii)	Percentage of shares (as a % of the total share capital of the company)	100%	100%	100%	100%	100%

	B. INVESTORS COMPLAINTS		3 Months ended 31.03.2014
	Pending at Begining of the Quarter		NIL
	Received During the Quarter		NIL
	Disposed of During the Quarter		NIL
	Remaining at the end of the Quarter		NIL

STATEMENT OF ASSETS AND LIAB ILITIES			(Rupees in '000')
Particulars			As at 31.03.2014	As at 31.03.2013
Particulars			(Audited)	(Audited)
A		EQUITY AND LIABILITIES
1		SHARE HOLDERS FUND
	a)	Share Capital	35,435	35,435
	b)	Reserves and Surplus	27,814	27,149
	Sub-Total of Shareholders Fund		63,249	62,584
2		NON CURRENT LIABILITIES
	a)	Long term borrowing	18,809	22,554
	b)	Deffered tax liability( net)	3,975	3,604
	c)	Other long term liability	168	147
	d)	Long term Provision	-	-
	Sub-Total of Non Current Liabilities		22,952	26,305
3		CURRENT LIABILITIES
	a)	Short term borrowing	-	-
	b)	Trade payable	8,497	4,013
	c)	Other current liabilities	5,221	5,652
	d)	Short term provision	-	-
	Sub-Total of Current Liabilities		13,718	9,665

		Total ( 1+2+3)	99,919	98,554

B		ASSETS
1		NON CURRENT ASSETS
	a)	Fixed Assets	37,165	39,761
	b)	Non current investments	3,159	3,159
	c)	Long term loans and advances	13,343	13,543
	d)	Other Non current assets	2,316	599
	Sub-Total of Non Current Assets		55,983	57,062
2		CURRENT ASSETS
	a)	Inventories	17,169	18,606
	b)	Trade receivable	13,334	12,717
	c)	Cash and cash equivalents	12,013	9,384
	d)	Short term loans and advances	1,420	785
		Sub-Total of Current Assets	43,936	41,492

		Total ( 1+2 )	99,919	98,554

NOTES :-

The above financial results have been taken on record at a meeting of Board of Directors held on 30-05-2014
The Company operates in single segment of manufacture of pharmaceutical formulations. Hence Accounting Standard on segment reporting is not applicable.
Previous period figures have been regrouped wherever required.